Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gasherbrum Bio Inc. currently has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 5 distinct art units. This indicates that while most applications are in different art units, at least two applications are likely being reviewed within the same administrative group, though by different examiners. The presence of 6 pending office actions reflects an active phase of patent prosecution.
CHANDRAKUMAR, NIZAL S is the busiest examiner, with 1 pending office action. Since 6 distinct examiners are involved in 6 pending office actions, each examiner is responsible for exactly one matter. This distribution suggests a range of biotechnological innovations that require specialized review from several different experts across 5 distinct art units. Practitioners must manage six separate examiner relationships while coordinating strategies across the 5 distinct art units to ensure consistency in the company pharmaceutical portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248857 | HETEROCYCLIC GLP-1 AGONISTS | BELL, SARA ELIZABETH | 44d overdue |
| 17799609 | HETEROCYCLIC GLP-1 AGONISTS | BAUER, NICOLA MARIA | 30d overdue |
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | CHANDRAKUMAR, NIZAL S | — |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1691 | 1 |
| 1624 | 1 |
| 1623 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | CHANDRAKUMAR, NIZAL S | 1625 | §112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18759609 | HETEROCYCLIC AGONISTS | RAHMANI, NILOOFAR | 1691 | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18248858 | HETEROCYCLIC GLP-1 AGONISTS | NOLAN, JASON MICHAEL | 1623 | §102 | Non-Final OA | — | Pending | Apr 12, 2023 |
| 18248857 | HETEROCYCLIC GLP-1 AGONISTS | BELL, SARA ELIZABETH | 1625 | §112DP | Final Rejection | 44d overdue | Pending | Apr 12, 2023 |
| 17799609 | HETEROCYCLIC GLP-1 AGONISTS | BAUER, NICOLA MARIA | 1621 | §103 | Non-Final OA | 30d overdue | Pending | Aug 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGasherbrum Bio Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Nizal S Chandrakumar has the most, with 1 of Gasherbrum Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
